Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Biotechnology
- Disease
- Delivery
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2768
IPSCIO Record ID: 279378
For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.
For the profit sharing products
For the Development Licenses, to Develop Profit-Sharing Products in such Program in the Field in the Territory; and Licensor grants a worldwide, Co-exclusive license, sublicenseable to its Affiliates, under and to any and all Licensor RNAi Technology, Licensor RNAi Patent Rights, Licensor Collaboration Inventions, Licensor Therapeutic Collaboration IP, Licensors interest in Joint Collaboration IP and Licensor RNAi Novel Target IP which are Controlled by Licensor or the Third Party Licensor or their wholly-owned subsidiaries to Develop Profit-Sharing Products in such Program in the Field in the Territory.
For the Commercialization Licenses, upon Licensees exercise of its U.S. Co-Promotion Option, Licensor grants Licensee a Co-exclusive license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the United States.
For the Manufacturing Licenses, Licensor grants Licensee a non-exclusive license under and to any and all Licensor Technology to Manufacture Profit-Sharing Products in the Field for the Territory.
For the Product Trademark Licenses, Licensor shall grant a Co-exclusive license to use such Product Trademarks to perform its Development obligations under this Agreement with respect to such Profit-Sharing Product.
Licensor grants a Co-exclusive license to use the Product Trademarks selected by Licensor and approved by the JSC for such Profit-Sharing Product to Commercialize such Profit-Sharing Product in the Field in the United States.
Licensor grants a non-exclusive license in the Territory, under Licensor Broad RNAi Patent Rights that were Controlled by Licensor or the Third Party Licensor or their wholly-owned subsidiaries during the Technology Collaboration Term, Licensor Broad RNAi Technology that was Controlled by Licensor or the Third Party or their wholly-owned subsidiaries during the Technology Collaboration Term, Licensors interest in Joint Collaboration Patent Rights, and Licensor-Assigned Therapeutic Collaboration Inventions.
Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.
IPSCIO Record ID: 3499
Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.
Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.
IPSCIO Record ID: 344538
The collaboration shall continue as stated in the original agreement, with this Pursuing Party change. The original agreement has conditional exclusivity.
The field as identified in the original agreement means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
IPSCIO Record ID: 280643
For the RHOA Target, pursuant to the terms of the Original Agreement, Licensor selected the RHOA Target for the development of RNAi Products directed toward such Target (RHOA Products) and Licensee has an opt-in right for further development and commercialization of RHOA Products.
For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.
For the Profit-Sharing Products
For Development Licenses, Licensor grants a worldwide license in the Territory, with a right to sublicense to its Affiliates, under Licensor Target Identification and Target Validation RNAi Patent Rights, under Licensors interest in Joint Collaboration Patent Rights and Joint Collaboration Inventions, under Licensor Technology Collaboration Inventions, to Licensor RNAi Technology and under Licensor-Assigned Therapeutic Collaboration Inventions, for the sole purpose of in vitro and/or in vivo target identification and/or target validation research relating to drug discovery and/or development activities of Licensee and/or its Affiliates, including in collaborations with Third Parties in which Licensee and/or its Affiliates has any rights to discoveries made.
For Commercialization Licenses, Licensor grants a license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the Territory.
The foregoing license shall be Exclusive, Co-exclusive or Non-exclusive, depending upon the time period.
Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.
Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF),[1] is a signal protein produced by cells that stimulates the formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors.
